天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

VOLUNTARY ANNOUNCEMENT
SIGNING OF STRATEGIC COOPERATION AGREEMENT

This announcement is made by Tianjin TEDA Biomedical Engineering Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of providing shareholders and potential shareholders of the Company the latest information regarding the business development of the Group.

SIGNING OF STRATEGIC COOPERATION AGREEMENT

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 21 July 2025, Beijing Boya Quanjian Intelligent Computing Technology Co., Ltd.（北京博雅全健智算科技有限公司）("**Boya Quanjian**"), a subsidiary of the Group, entered into a strategic cooperation framework agreement with China Telecom Digital Intelligence Technology Co., Ltd., Ningxia Branch ("**CT**"). Both parties will give full play to their respective advantages in resources, talents and technologies to establish a long-term strategic cooperation in the areas of medical and healthcare big data application, AI application scenarios implementation, including online and offline specialised operation, channel development as well as transformation of achievements of above areas.

REASONS FOR AND BENEFITS OF SIGNING THE STRATEGIC COOPERATION AGREEMENT

The Board believes that the signing of the strategic cooperation agreement enables leveraging CT's strong network resources, computing power support, infrastructure and data advantages in the Ningxia region and give full play to Boya Quanjian's technological research and development strength in the field of convergence of AI and medical and healthcare and its capability to transform scientific research results, in an effort to achieve mutual complementarity of resources and win-win co-operation. Through the cooperation, Boya Quanjian can accelerate the research and development of vertical AI medical and healthcare technology and scenario-based implementation, and further strengthen the core competitiveness in the field of "AI + Medical and Healthcare", and help the Company expanding its business scale and growing industry influence.

STRATEGIC COOPERATION AGREEMENT

Boya Quanjian and CT intend to conduct strategic cooperation in the following aspects:

1. **Establishing a foundational R&D platform for healthcare.** Boya Quanjian, leveraging the foundational platform of CT, establishes a basic platform framework for healthcare vertical training and inference, which integrates major modules such as molecular biology, medical imaging, genomics and medical robotics.

2. **Promoting the implementation of key AI health management application scenarios.** CT provides computing power, cloud computing, security, and foundational platform support, while Boya Quanjian utilizes its strengths in R&D and the commercialization of scientific research achievements. Together, they promote the application and implementation of large-scale models, including AI Health Profiling, AI Health Management (Triage, Medication Guidance) Assistant, AI Remote ECG Monitoring, AI Nutrition and Wellness Management and AI Mental Health and Sleep Management.

3. **Jointly establishing a trusted data space and high-quality datasets for health management.** Capitalizing on their respective resources and strengths, both parties collaborate to build a trusted data space for the health management industry, promote the development of high-quality healthcare datasets, and enhance the data circulation system.

4. **Building Ningxia "AI + Healthcare" Industrial Park.** Riding on their respective resources and strengths, the two parties join hands to build an "Artificial Intelligence + Healthcare" Industrial Park. Boya Quanjian is responsible for transforming AI-driven healthcare research achievements into practical applications and introducing leading (or with immense growth potential) domestic AI enterprises and research institutions, thereby foster an integrated platform for health management that combines "production, education, research and application".

5. **Collaboration on intellectual resources.** The two parties establish an expert advisory committee to provide policy consultation, ethical oversight, technical support and expert resources for AI-enabled health management. The committee also facilitates the scientific management and active integration of additional stakeholders to promote ecosystem development together.

INFORMATION ON BOYA QUANJIAN

The shareholders of Boya Quanjian are wholly-owned subsidiaries of the Company, namely Ningxia Hongdi Biotechnology Co., Ltd. and Beijing Qingniao Kechuang Technology Co., Ltd. ("**Beijing Qingniao**"), and the core management team, holding 60%, 5% and 35% of shares, respectively. The actual controlling party of Beijing Qingniao is Beida Asset Management Co., Ltd.

Boya Quanjian focuses on the deep integration of artificial intelligence and medical health technology, and has built a full-chain operation system of "technology research and development－scenario determination－industrial empowerment". On one hand, relying on the medical health software platform of the Company, Boya Quanjian collaborates with hospitals affiliated with Peking University Health Science Center to deeply utilize data from various medical segments and develop large application models for medical segments that meet the needs of different scenarios. On the other hand, by building an open and collaborative ecological platform, Boya Quanjian collaborates with research institutes, medical institutions, and upstream and downstream enterprises of the industrial chain to continuously enhance the efficiency of technology transformation and scenario determination in areas such as AI-assisted diagnosis.

INFORMATION ON CT

The controlling shareholder of CT is China Telecom Group ("**China Telecom**"). China Telecom builds and operates the largest medical cloud zone, government information innovation cloud and e-government extranet in Ningxia region. Relying on China Telecom's strong network resources, technical strength and brand influence, CT provides enterprises with services such as cloud service platforms, big data analysis solutions, AI intelligent applications and Internet of Things integration.

<div align="center">

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

</div>

Tianjin, the PRC
21 July 2025

As at the date of this announcement, the executive director of the Company is Ms. Sun Li; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive directors of the Company are Mr. Wang Yongkang, Ms. Gao Chun and Mr. Tu Xiangzhen.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the "Latest Company Information" page for seven days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.